20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- Science in Berlin: collaborative, diverse, innovative, internationalScience is a key social and economic factor for Berlin. It creates jobs and adds value, attracts talent from all over the world, and enriches city life. To ensure that Berlin remains one of the world’s leading centres of science in the future, science must feature even more prominently on the political agenda. This is what BR50 stands for: over 50 non-university research institutions, including the HZB, are joining forces in this network. Following the election in Berlin, BR50 is now addressing politicians with a position paper, accompanied by the campaign “𝗪𝗶𝗿 𝗳𝗼𝗿𝘀𝗰𝗵𝗲𝗻 𝗳ü𝗿 𝗕𝗲𝗿𝗹𝗶𝗻.”
- Does African Architecture exist?The world’s first Pan-African Architecture Biennale took place this September in Nairobi, Kenya. People from the worlds of architecture, art, academia and politics from 54 African countries and the diaspora had travelled to Nairobi to exchange ideas on traditional and contemporary building methods, materials, experiences and projects. Samira Aden co-organised this biennial as lead curator. We spoke to her about it.
- Nanosilver as an electrocatalyst for CO₂ reductionVia electrolysis, CO2 can be reduced to CO, a raw material for further chemical products such as fuels. Within the GreenQuest Project, an internation team led by HZB chemist Prashanth Menezes has now systematically investigated catalyst layers made of silver nanoparticles, varying both the size of the particles and their density. The best yield was achieved with nanoparticles with diameters of around 10 nm, which were loosely distributed. Furthermore, they demonstrated how the economic efficiency of the electrochemical cell can be enhanced by integrating an additional chemical reaction at the anode, enabling the simultaneous production of a valuable formic acid, hydrogen, and CO in one device.